The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Genmab
 
Other Relationship - Takeda
Epcoritamab (GEN3013; DuoBody-CD3×CD20) to induce complete response in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL): Complete dose escalation data and efficacy results from a phase I/II trial.
 
Martin Hutchings
No Relationships to Disclose
 
Pieternella Lugtenburg
Honoraria - Celgene; Genmab; Janssen-Cilag; Roche; SERVIER; Takeda
Speakers' Bureau - Roche
Research Funding - Roche; SERVIER; Takeda
 
Rogier Mous
Honoraria - Abbvie; Bristol-Myers Squibb; Celgene; Gilead Sciences; Janssen-Cilag; MSD; Roche; Sandoz; Takeda
Consulting or Advisory Role - Gilead Sciences; Janssen-Cilag
Research Funding - Gilead Sciences; Takeda
 
Michael Roost Clausen
Travel, Accommodations, Expenses - Abbvie
 
Martine Chamuleau
No Relationships to Disclose
 
Kim Linton
Honoraria - Roche
Consulting or Advisory Role - Celgene; Roche; Takeda
Research Funding - Roche
Travel, Accommodations, Expenses - Roche; Takeda
 
Simon Rule
No Relationships to Disclose
 
Juanita Suzanne Lopez
Consulting or Advisory Role - Genmab; Novartis
Research Funding - Basilea (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Basilea; Roche/Genentech
 
Roberto S Oliveri
Employment - Genmab
Stock and Other Ownership Interests - Genmab
 
Dena DeMarco
Employment - Genmab
Stock and Other Ownership Interests - Genmab
 
Brian Elliott
No Relationships to Disclose
 
Peter Johnson
Honoraria - Bristol-Myers Squibb; Celgene; Genmab; Incyte; Kite, a Gilead company; Kymera; MorphoSys; Novartis; Takeda
Consulting or Advisory Role - Boehringer Ingelheim; Epizyme; Janssen; Oncimmune
Research Funding - Epizyme (Inst)
Patents, Royalties, Other Intellectual Property - Combined use of Fc gamma RIIb (CD32b) and CD20 - specific antibodies. WO Patent, PCT/GB2011/051572; EU11760819.0